BioCentury
ARTICLE | Company News

GB Therap, Chiesi Farmaceutici SpA deal

August 16, 2004 7:00 AM UTC

GB acquired from Chiesi worldwide rights to GT3381 ( CHF3381), a small molecule NMDA antagonist and MAO-A inhibitor to treat neuropathic pain. The compound has completed Phase Ia and Phase Ib trials...